Skip to main content
. 2020 Mar 13;10:4662. doi: 10.1038/s41598-020-61688-7

Table 1.

Immunohistochemical expression in patients with metastatic (n = 25) and non-metastatic (n = 26) sporadic colorectal cancer (sCRC) at diagnosis.

Marker Non-metastatic sCRC (n = 26) Metastatic sCRC (n = 25) p Total (n = 51)
MLH1
Loss 5 (20%) 0 (0%) 0.050 5 (10%)
Normal 20 (80%) 25 (100%) 45 (90%)
Excluded 1 0 1
PMS2
Loss 6 (25%) 0 (0%) 0.020 6 (14%)
Normal 18 (75%) 18 (100%) 36 (86%)
Excluded 2 7 9
MSH2
Loss 2 (8%) 0 (0%) NS 2 (4%)
Normal 22 (92%) 23 (100%) 45 (96%)
Excluded 1 2 3
MSH6
Loss 2 (8%) 0 (0%) NS 2 (4%)
Normal 23 (92%) 24 (100%) 47 (96%)
Excluded 1 1 2
c-Myc
<10% 2 (8%) 7 (29%) NS 9 (19%)
≥10% 22 (92%) 17 (71%) 39 (81%)
Excluded 2 1 3
Her2
0/1+ 26 (100%) 23 (96%) NS 49 (98%)
2+ 0 (0%) 0 (0%) 0 (0%)
3+ 0 (0%) 1 (4%) 1 (2%)
Excluded 0 1 1
p53
0 6 (23%) 7 (29%) NS 13 (26%)
<10% 9 (35%) 6 (35%) 15 (30%)
≥10% 11(42%) 11 (46%) 22 (44%)
Excluded 0 1 1
β-catenin
Negative 18 (69%) 11 (46%) NS 29 (58%)
Positive 8 (31%) 13 (54%) 21 (42%)
Excluded 0 1 1
CEA
Negative 11 (22%) 0 (0%) <0.001 11 (22%)
Positive 15 (88%) 24 (100%) 39 (78%)
EGFR
0 16 (62%) 5 (21%) <0.001 21 (42%)
1–10% 4 (15%) 1 (4%) 5 (10%)
10–35% 6 (23%) 4 (17%) 10 (20%)
>35% 0 14 (58%) 14 (28%)
Excluded 0 1 1
Ki-67
<50% 15 (58%) 19 (83%) NS 34 (69%)
≥50% 11 (42%) 4 (17%) 15 (31%)
Excluded 0 2 2

Results expressed as number of cases (percentage); CEA: carcinoembryogenic antigen; NS: no statistically significant differences found between groups (p > 0.05). Cases excluded due to technical problems were not considered in the statistical analysis.